-
09.24.2018 | CARB-X calls for new ‘open science’ era in antibacterial innovation: Sharing scientific data will help speed the delivery of new antibiotics and other life-saving products to fight superbugs
Achaogen will share valuable LpxC compounds and data with Forge Therapeutics, with both companies leading the ‘open science’ initiative among CARB-X-funded companies
-
09.20.2018 | CARB-X 2017-18 Annual Report is now online
CARB-X’s second year was highlighted by a growing pipeline, global partnership and exciting science in the fight against superbugs
-
07.31.2018 | CARB-X funds SciBac to develop a microbe drug that kills C. difficile superbugs
An alternative to antibiotics, this microbe pill would boost the body’s microbiome to kill the Clostridium difficile bacteria and prevent recurrent C. difficile infections known as deadly diarrhea
-
07.10.2018 | CARB-X funds Summit Therapeutics to support development of a new class of antibiotics to treat Gonorrhoea Superbug
CARB-X awards Summit Therapeutics $2 million in non-dilutive funding, with the possibility of up to $2.5 million more, to support the development of a new class of antibiotics to treat gonorrhoea. This project bring to 10 the number of new classes in the portfolio; 34 projects to fight superbugs
-
05.22.2018 | UK Government and Bill & Melinda Gates Foundation join CARB-X partnership in fight against superbugs
The UK Government’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Bill & Melinda Gates Foundation (BMGF) have joined the CARB-X partnership to support scientific research around the world to develop new vaccines, preventatives, and other products against drug-resistant bacterial infections, particularly among vulnerable populations in low- and middle-income countries.
-
05.15.2018 | CARB-X funds MicrobeDx to support development of a transformative testing system to rapidly diagnose life-threatening infections in the urinary tract
MicrobeDx’s system could diagnose infections and identify the bug causing it within 30 minutes, and tell doctors within three hours which antibiotic to prescribe to kill the bacteria
-
05.10.2018 | CARB-X funds Talis Biomedical to develop systems to diagnose chlamydia and gonorrhea within minutes and determine which antibiotics would kill the bacteria
CARB-X is awarding Talis Biomedical Corporation of Menlo Park, CA, up to $4.4 million, with the possibility of up to $4.2 million more based on achievement of project milestones, to support the development of the company's molecular diagnostic system which would speed diagnosis and appropriate treatment of chlamydia and gonorrhea, including drug-resistant infections.
-
05.07.2018 | CARB-X partners with Melinta Therapeutics to accelerate the development of a new class of antibiotic to battle multiple life-threatening superbugs
CARB-X is teaming up with Melinta Therapeutics (NASDAQ: MLNT) to support the development of a new class of antibiotic called pyrrolocytosine to treat the most serious drug-resistant bacterial infections.
-
04.26.2018 | CARB-X announces award to Achaogen to advance the development of next-generation aminoglycoside antibiotic to treat highly-resistant gram-negative pathogens
CARB-X is funding Achaogen, Inc. (NASDAQ: AKAO) of South San Francisco, CA, to support the development of a next-generation broad-spectrum aminoglycoside antibiotic capable of overcoming resistance mechanisms and potentially treating highly-resistant pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii.
-
04.20.2018 | CARB-X funds Idorsia to accelerate the early development of a new class of antibiotic to treat deadly drug-resistant bacterial infections
CARB-X announced today a funding agreement with Idorsia (SIX: IDIA.S) of Allschwil, Switzerland, to support the development of a new class of antibiotic, a novel dual-acting topoisomerase inhibitor, to treat patients with infections caused by drug-resistant bacteria.
-
04.03.2018 | CARB-X funds Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood
Specific's antibiotic susceptibility testing system promises accurate drug susceptibility and identification of superbugs within 4 hours of a positive blood sample, reducing the chance of life-threatening sepsis and other urgent complications of blood infections.
-
03.22.2018 | CARB-X funds Shionogi to develop an antibiotic to treat infections caused by the life-threatening CRE superbug
CARB-X is funding Shionogi of Osaka, Japan, to support the development of a novel β-lactam antibiotic with potent activity against the dreaded superbug serine- and metallo-type carbapenemase-producers, including BL/BLI-resistant carbapenem-resistant Enterobacteriaceae (CRE)
-
03.15.2018 | CARB-X teams up with HelixBind to support the development of a test to diagnose life-threatening bloodstream infections linked to sepsis
CARB-X is awarding HelixBind of Marlborough, MA, up to $1 million, with the possibility of up to $1 million more based on achievement of project milestones, to support the development of the company's RaPID/BSI diagnostic test for invasive bloodstream infections.
-
03.06.2018 | CARB-X partners with T2 Biosystems to develop tests to identify and diagnose drug-resistant bacteria direct from blood
CARB-X is funding T2 Biosystems, Inc. of Lexington, MA (NASDAQ: TTOO) to support the development of new tests using the company's T2 Magnetic Resonance technology that would enable doctors to quickly diagnose and treat life-threatening, drug-resistant bacterial infections in whole blood.
-
03.05.2018 | CARB-X partners with MicuRx to develop a polymyxin antibiotic to treat multi-drug resistant Gram-negative superbugs including E. coli, P. aeruginosa, K. pneumoniae and A. baumannii
CARB-X is teaming up with MicuRx Pharmaceuticals Inc. of Hayward, CA, to support the early development of its polymyxin antibiotic MRX-8 to treat the most serious multi-drug-resistant bacterial infections, including infections caused by Gram-negative pathogens E. coli, P. aeruginosa, K. pneumoniae and A. baumannii.
-
03.01.2018 | CARB-X partners with Macrolide Pharmaceuticals to develop novel macrolide antibiotics with Gram-negative activity
CARB-X is funding Macrolide Pharmaceuticals of Watertown, MA, to support the development of a novel fully synthetic, orally available macrolide antibiotic with Gram-negative activity, with the aim of treating serious infections including drug-resistant complicated urinary tract infections (cUTI).
-
02.20.2018 | CARB-X launches its 2018 rounds of funding and invites applications
CARB-X announced today its 2018 rounds of funding to support research into the development of antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria.
-
02.15.2018 | CARB-X teams up with Curza to develop a new class of antibiotics to treat drug-resistant Gram-negative bacteria
CARB-X is funding Curza of Salt Lake City, UT, to support the development of a new class of antibiotics to treat a broad spectrum of life-threatening Gram-negative bacteria that are resistant to existing antibiotics.
-
01.24.2018 | New global approach and greater financial incentives needed to drive antibiotic innovation, concludes Drive-AB final study on combating the global drug resistance threat
$1-billion market-entry reward for each new antibiotic approved, doubling research investment for groups like CARB-X, and new concerted approach needed to drive antibiotic innovation and ensure access and sustainable use
-
01.23.2018 | Carb-X Is Seeking Additional Accelerators To Expand Support For Its Growing Early Development Antibacterial Pipeline
CARB-X is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. Applications are welcome until March 30, 2018.
Toggle navigation